Numinus Wellness (NUMIF) Stock Price, News & Analysis

Company Overview

Numinus Wellness Inc is a Canada-based company focused on the development and delivery of psychedelic-assisted therapies and mental health services. The company operates a network of wellness clinics across several provinces, offering guided psilocybin-assisted therapy sessions under Health Canada’s regulatory framework. Numinus integrates psychological support, medical oversight and integration counselling to address a range of mental health conditions, including depression, anxiety and post-traumatic stress disorder.

Through its Numinus Bioscience division, the company conducts research and development activities in psychedelic compounds such as psilocybin and other novel molecules. This division operates a federally licensed laboratory in Vancouver, British Columbia, providing analytical testing, quality control and manufacturing services for clinical trials and commercial programs. By maintaining end-to-end capabilities—from preclinical research to production—Numinus Bioscience supports the advancement of proprietary formulations and therapeutic protocols.

In addition to clinical operations, Numinus Wellness offers practitioner education and training programs designed to establish best practices in psychedelic-assisted therapy. The company has formed partnerships with academic institutions and healthcare organizations to co-develop research studies and professional curricula. Numinus also holds research licenses in key jurisdictions, including the state of Oregon in the United States, positioning it to conduct cross-border clinical investigations and expand access to regulated psychedelic treatments.

Founded in 2018 and led by Payton Nyquvest as Chair and Chief Executive Officer, Numinus Wellness is governed by a board of directors with backgrounds in biotechnology, healthcare and regulatory affairs. Its senior leadership team includes experts in clinical psychology, pharmaceutical development and laboratory operations. By leveraging a vertically integrated model encompassing research, manufacturing and service delivery, Numinus aims to advance the scientific understanding and accessibility of psychedelic medicine.

Key Stats

• Today's Range: C$0.03 to C$0.04
• 50-Day Range: C$0.02 to C$0.05
• 52-Week Range: C$0.01 to C$0.06
• Volume: 67,492 shs
• Average Volume: 120,371 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NUMIF
• CIK: N/A
• Web: www.numinus.com
• Phone: (604) 649-3229
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A